PL3603620T3 - Kompozycja liposomowa i kompozycja farmaceutyczna - Google Patents
Kompozycja liposomowa i kompozycja farmaceutycznaInfo
- Publication number
- PL3603620T3 PL3603620T3 PL18776957.5T PL18776957T PL3603620T3 PL 3603620 T3 PL3603620 T3 PL 3603620T3 PL 18776957 T PL18776957 T PL 18776957T PL 3603620 T3 PL3603620 T3 PL 3603620T3
- Authority
- PL
- Poland
- Prior art keywords
- composition
- liposome
- pharmaceutical composition
- pharmaceutical
- liposome composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017069836 | 2017-03-31 | ||
| PCT/JP2018/013783 WO2018181963A1 (ja) | 2017-03-31 | 2018-03-30 | リポソーム組成物および医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3603620T3 true PL3603620T3 (pl) | 2026-02-16 |
Family
ID=63676279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18776957.5T PL3603620T3 (pl) | 2017-03-31 | 2018-03-30 | Kompozycja liposomowa i kompozycja farmaceutyczna |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11413244B2 (pl) |
| EP (1) | EP3603620B1 (pl) |
| JP (3) | JP6728482B2 (pl) |
| KR (1) | KR102328463B1 (pl) |
| CN (4) | CN116763733A (pl) |
| AU (1) | AU2018246024B2 (pl) |
| BR (1) | BR112019020406B1 (pl) |
| CA (1) | CA3058127C (pl) |
| DK (1) | DK3603620T3 (pl) |
| ES (1) | ES3055110T3 (pl) |
| FI (1) | FI3603620T3 (pl) |
| HR (1) | HRP20251519T1 (pl) |
| LT (1) | LT3603620T (pl) |
| PL (1) | PL3603620T3 (pl) |
| PT (1) | PT3603620T (pl) |
| RS (1) | RS67470B1 (pl) |
| RU (1) | RU2734900C1 (pl) |
| SI (1) | SI3603620T1 (pl) |
| SM (1) | SMT202500440T1 (pl) |
| WO (1) | WO2018181963A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018181963A1 (ja) | 2017-03-31 | 2018-10-04 | 富士フイルム株式会社 | リポソーム組成物および医薬組成物 |
| PL3811931T3 (pl) * | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| WO2020071349A1 (ja) * | 2018-10-01 | 2020-04-09 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
| AU2019400340A1 (en) * | 2018-12-17 | 2021-05-20 | Eisai R&D Management Co., Ltd. | Formulation comprising liposomes |
| US11154501B2 (en) | 2019-08-09 | 2021-10-26 | Nanophase Technologies Corporation | Method of enhancing the efficacy and stability of ingredients in suspensions |
| TW202207904A (zh) * | 2020-05-06 | 2022-03-01 | 美商納米科技製藥公司 | 用於治療癌症及癌症抗藥性之脂質體調配物 |
| CN113876711A (zh) * | 2020-07-01 | 2022-01-04 | 江苏长泰药业有限公司 | 一种盐酸阿霉素脂质体的制备工艺 |
| TW202237069A (zh) * | 2020-12-14 | 2022-10-01 | 美商納米科技製藥公司 | 用於遞送具經改良的治療指數之抗癌藥劑之組合物與方法 |
| JP6884496B1 (ja) * | 2021-03-08 | 2021-06-09 | ユーシービージャパン株式会社 | レベチラセタムを有効成分とする注射用製剤 |
| KR20230158044A (ko) | 2021-03-18 | 2023-11-17 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| CN113101374B (zh) * | 2021-04-08 | 2022-10-25 | 陕西科技大学 | 一种阿拉伯胶-明胶修饰牡丹籽油纳米脂质体及其制备方法 |
| WO2022250015A1 (ja) | 2021-05-24 | 2022-12-01 | 富士フイルム株式会社 | 処置剤 |
| EP4349337A4 (en) * | 2021-05-24 | 2024-08-28 | FUJIFILM Corporation | Anti-tumor agent |
| US20250177302A1 (en) * | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Liposome composition and liposome-containing pharmaceutical composition |
| WO2024111564A1 (ja) | 2022-11-21 | 2024-05-30 | 富士フイルム株式会社 | トポテカン又はその塩を内包するリポソーム組成物およびｄｎａ損傷修復阻害剤を含む組合せ医薬 |
| GB202315012D0 (en) * | 2023-09-29 | 2023-11-15 | Univ Bath | Composition |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| CA2346879A1 (en) | 1998-09-16 | 2000-04-27 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| EP1299085B1 (en) | 2000-06-30 | 2005-11-16 | Inex Pharmaceuticals Corp. | Improved liposomal camptothecins and uses thereof |
| US20080075762A1 (en) | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| US20070231379A1 (en) * | 2002-08-29 | 2007-10-04 | Slater James L | Liposome-entrapped topoisomerase inhibitors |
| AU2005251691A1 (en) * | 2004-05-17 | 2005-12-22 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| AU2005304914B2 (en) | 2004-11-05 | 2012-02-16 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US20070088414A1 (en) * | 2005-05-25 | 2007-04-19 | Campbell Robert L | Particulate formulations for intradermal delivery of biologically active agents |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| WO2009149150A2 (en) | 2008-06-03 | 2009-12-10 | Alza Corporation | Composition comprising liposome-entrapped doxorubicin and methods of administration |
| AR076634A1 (es) * | 2008-11-21 | 2011-06-29 | Medgenesis Therapeutix Inc | Composiciones y metodo para tratar desordenes del sistema nervioso central |
| WO2010110923A2 (en) | 2009-03-27 | 2010-09-30 | Robert Sabin | Prophylactic and therapeutic treatment of alzheimer's disease |
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| US11357728B2 (en) * | 2009-10-26 | 2022-06-14 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| WO2011092708A2 (en) * | 2010-02-01 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
| BR112013016365A2 (pt) | 2010-12-27 | 2018-06-26 | Terumo Corp | composição de lipossoma e processo para produção do mesmo |
| US20140328759A1 (en) * | 2011-10-25 | 2014-11-06 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
| CN102764234A (zh) | 2012-08-03 | 2012-11-07 | 上海现代药物制剂工程研究中心有限公司 | 一种盐酸拓扑替康靶向脂质体制剂及其制备方法 |
| CN104736201A (zh) * | 2012-10-19 | 2015-06-24 | 加利福尼亚大学董事会 | 治疗中枢神经系统的肿瘤 |
| CA2923029A1 (en) * | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| CN104771361B (zh) * | 2014-01-14 | 2018-06-01 | 中国科学院上海药物研究所 | 一种盐酸拓扑替康脂质体纳米制剂及其制备方法 |
| US10369104B2 (en) | 2014-04-01 | 2019-08-06 | Children's Hospital Los Angeles | Targeted polymerized nanoparticles for cancer treatment |
| JP6316182B2 (ja) * | 2014-12-19 | 2018-04-25 | 富士フイルム株式会社 | リポソームの製造方法及びリポソーム製造装置 |
| JP6602886B2 (ja) | 2015-11-02 | 2019-11-06 | 富士フイルム株式会社 | ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット |
| WO2017079303A1 (en) | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer |
| RU2761953C2 (ru) | 2016-11-02 | 2021-12-14 | Ипсен Биофарм Лтд. | Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин) |
| IL317919A (en) | 2016-12-05 | 2025-02-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| WO2018181963A1 (ja) | 2017-03-31 | 2018-10-04 | 富士フイルム株式会社 | リポソーム組成物および医薬組成物 |
| PL3811931T3 (pl) | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| WO2020071349A1 (ja) | 2018-10-01 | 2020-04-09 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
-
2018
- 2018-03-30 WO PCT/JP2018/013783 patent/WO2018181963A1/ja not_active Ceased
- 2018-03-30 CN CN202310994903.5A patent/CN116763733A/zh active Pending
- 2018-03-30 DK DK18776957.5T patent/DK3603620T3/da active
- 2018-03-30 KR KR1020197028183A patent/KR102328463B1/ko active Active
- 2018-03-30 SM SM20250440T patent/SMT202500440T1/it unknown
- 2018-03-30 CN CN202310994904.XA patent/CN116763734A/zh active Pending
- 2018-03-30 PL PL18776957.5T patent/PL3603620T3/pl unknown
- 2018-03-30 RS RS20251226A patent/RS67470B1/sr unknown
- 2018-03-30 FI FIEP18776957.5T patent/FI3603620T3/fi active
- 2018-03-30 BR BR112019020406-7A patent/BR112019020406B1/pt active IP Right Grant
- 2018-03-30 HR HRP20251519TT patent/HRP20251519T1/hr unknown
- 2018-03-30 EP EP18776957.5A patent/EP3603620B1/en active Active
- 2018-03-30 ES ES18776957T patent/ES3055110T3/es active Active
- 2018-03-30 LT LTEPPCT/JP2018/013783T patent/LT3603620T/lt unknown
- 2018-03-30 RU RU2019130500A patent/RU2734900C1/ru active
- 2018-03-30 PT PT187769575T patent/PT3603620T/pt unknown
- 2018-03-30 SI SI201831273T patent/SI3603620T1/sl unknown
- 2018-03-30 JP JP2019509395A patent/JP6728482B2/ja active Active
- 2018-03-30 CN CN201880023073.9A patent/CN110505869A/zh active Pending
- 2018-03-30 CN CN202111595172.4A patent/CN114224840A/zh active Pending
- 2018-03-30 AU AU2018246024A patent/AU2018246024B2/en active Active
- 2018-03-30 CA CA3058127A patent/CA3058127C/en active Active
-
2019
- 2019-09-26 US US16/583,518 patent/US11413244B2/en active Active
-
2020
- 2020-07-01 JP JP2020113828A patent/JP7012124B2/ja active Active
- 2020-10-26 US US17/079,759 patent/US11446247B2/en active Active
-
2022
- 2022-01-17 JP JP2022005193A patent/JP7278436B2/ja active Active
- 2022-08-05 US US17/882,144 patent/US20220370352A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL293377A (en) | Hsd17b13 variants and uses thereof | |
| IL289276A (en) | Treprostinil derivatives and compositions and uses thereof | |
| DK3603620T3 (da) | Liposomsammensætning og farmaceutisk sammensætning | |
| IL271275A (en) | Compositions comprising curons and uses thereof | |
| EP3513809A4 (en) | MEDICAL COMPOSITION | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| PL3319612T3 (pl) | Oksysterole i sposoby ich stosowania | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| SI3672948T1 (sl) | Piridinamin-piridon in spojine pirimidinamin-piridona | |
| EP3603642A4 (en) | PHARMACEUTICAL PREPARATION | |
| IL271073A (en) | B4galt1 variants and uses thereof | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| EP3417845A4 (en) | ALPHA FORMULATION COMPOSITION AND ALPHA YELLOW COMPOSITION | |
| MA49905A (fr) | Polyesteramines et polyesterquats | |
| IL282157A (en) | Compounds and therapeutic uses thereof | |
| IL269305A (en) | Cannabinoid formulations and dosage | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf | |
| DK3601277T3 (da) | Farmaceutisk formulering | |
| EP3441073A4 (en) | MEDICAL COMPOSITION | |
| EP3305309A4 (en) | ANTICARIOGENIC AGENT AND ANTICARIAC COMPOSITION |